Plasmalogen Tests
Biochemistry is a living and active process inside your body. The Plasmalogen Blood Test measures key biochemical systems to understand your biochemical health. You can take control of these systems to optimize health for longevity.
Not only are the biomarkers we measure critical for optimal health, dysfunctional levels are scientifically linked to increased risk of diseases including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, heart disease, stroke, and diabetes.
ProdromeScan is a multi-system blood test, specifically designed to assist Functional Medicine doctors and biohackers in achieving optimal biochemical health for themselves and their patients. Your biochemistry is personal. With this ground breaking test the secrets of your biochemistry are revealed, in a useful way. This test allows you to objectively measure, track and optimise performance of a targeted intervention strategy.
The ProdromeScan test measures approximately 100 biomarkers organised into specific biosystems known to be associated with advanced health and longevity. ProdromeScan evaluates both biosystem reserve capacity and biosystem function. Each of the biosystems measured is modifiable using targeted lifestyle, supplementation and diet based strategies.
The PlasmalogenPLUS test measures plasmalogen molecules in addition to key ethanolamine phospholipids. It is a simplified version of the comprehensive ProdromeScan test, and is therefore offered at a lower cost.
PRODROMESCAN BIOMARKERS:
Membrane Lipids:
Ethanolamine Plasmalogens
Choline Plasmalogens
Phosphatidyl ethanolamines
Phosphatidyl cholines
Sphingomyelins
Cholesterol
Membrane Lipid breakdown products:
Lysophosphatidyl cholines
Phosphorylcholine
Diacylglycerols
Ceramides
Free fatty acids (DHA, DPA, EPA, AA, LA, OA)
Lipid storage:
Triacylglycerols
Anti-inflammatory lipids
Gastrointestinal Tract Acids GTAs
Key Lipid ratios:
Omega-3/6
Omega-3/9
Plasmalogen choline to Phosphatidylcholine
Ethanolamine plasmalogen to Phosphatidyl ethanolamine
Sphingomyelin to Ceramide
Blood test Logistics
The test fee includes the blood draw, serum processing, shipping to our facility within Australia and then on to the USA, and the patented lab test analysis in the USA.
The tests are only offered through these participating pathology companies:
Laverty
QML
Abbott Pathology
Dorevitch Pathology
TML Pathology
WDP (Western Diagnostic Pathology)
Once testing is complete, results and detailed report are sent via email.
The report will be ready 10 to 14 days after the sample arrives in the USA laboratory.
BLOOD TEST PUBLICATIONS
Plasmalogen deficiency and neuropathology in Alzheimer’s disease: Causation or coincidence? Alzheimer’s & Dementia TRCI 5: Doi 10.1016/j.trci.2019.08.003
Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci 9: Doi 10.3390/brainsci9040092
Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC neurology, 15, 154. doi:10.1186/s12883-015-0411-4
Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 13: 416 Doi 10.1186/1471-2407-13-416
Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35: 59-62
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 48: 2485-2498 Doi 10.1194/jlr.P700023-JLR200
Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 21(21): 6604-6612
Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer 132: 355-362 Doi 10.1002/ijc.27673
Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013, 13:416
Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res 30: 59 Doi 10.1186/1756-9966-30-59
Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8: 13 Doi 10.1186/1741-7015-8-13
Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 10: 140 Doi 10.1186/1471-230X-10-140
Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. Pancreas. 2016;45:1418-23.
Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.